Liberia
Tuberculosis profile
| High HIV burden |
Population  2012 4.2 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.9 (0.83–3.5) 46 (20–84)
Mortality (HIV+TB only) 0.23 (0.17–0.3) 5.6 (4.1–7.2)
Prevalence  (includes HIV+TB) 21 (10–35) 495 (244–832)
Incidence  (includes HIV+TB) 13 (11–15) 304 (251–362)
Incidence (HIV+TB only) 0.76 (0.61–0.93) 18 (15–22)
Case detection, all forms (%) 64 (53–77)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 4 342 (54) Relapse 56 (59)
Smear-negative 1 233 (15) Treatment after failure 10 (11)
Smear-unknown / not done 713 (9) Treatment after default 29 (31)
Extrapulmonary 1 749 (22) Other 0 (0)
Other 0 (0)      
Total new 8 037   Total retreatment 95  
           
Other (history unknown) 0        
Total new and relapse 8 093   Total cases notified 8 132  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.2 1.5 1.2
Age < 15 126 343 213
Laboratories 2012
Smear (per 100 000 population) 3.9
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 86   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 89  
Retreatment 82  
TB/HIV 2012 Number (%)
TB patients with known HIV status 5 661 (70)
HIV-positive TB patients 772 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 693 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 115 (15)
HIV-positive people screened for TB 8 875  
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
110 (6–210) 18 (7–29)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     6
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions) 12
% Funded domestically <1%
% Funded internationally 37%
% Unfunded 62%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-18 Data: www.who.int/tb/data